Clinical Trials Logo

Hyperglycemia clinical trials

View clinical trials related to Hyperglycemia.

Filter by:

NCT ID: NCT05392452 Completed - Clinical trials for Diabetes Mellitus, Type 2

Fully Closed-Loop Insulin Delivery in Abdominal Surgery (CLAB)

CLAB
Start date: August 9, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the efficacy, safety and usability of perioperative fully-automated closed-loop insulin delivery versus standard insulin therapy in patients with diabetes other than type 1 diabetes undergoing elective major abdominal surgery.

NCT ID: NCT05365152 Recruiting - Diabetes Clinical Trials

The Effect of Meal Replacement on the Time to Reach the Blood Glucose Target in Patients With Type 2 Diabetes Mellitus

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

This study was designed as a randomized controlled study. It was planned to include 100 patients with type 2 diabetes who received short-term intensive insulin therapy and randomly divided them into a meal replacement intervention group and a conventional diabetes diet group according to 1:1. Both groups were treated with short-term intensive insulin therapy to control blood sugar. .

NCT ID: NCT05349916 Completed - Type2 Diabetes Clinical Trials

The Attenuating Effect of Soluble Fiber Consumption on Postprandial Glycemia in Humans

Start date: December 7, 2021
Phase: N/A
Study type: Interventional

The main objective of the current study is to investigate whether consumption of soluble fibers (isomaltodextrin [IMD], partially digestible maltodextrin) and RS4 starch will lower postprandial glycemia as well as postprandial insulin in human subjects with relatively high fasting blood glucose, when consumed with a specific amount of digestible carbohydrate (rice porridge). The primary outcome of the study is the effect of fibers on postprandial blood glucose, whereas the secondary outcome will be its effect on postprandial blood insulin.

NCT ID: NCT05343494 Completed - PreDiabetes Clinical Trials

Maternal Health Diabetes Prevention Study

Start date: April 4, 2022
Phase: N/A
Study type: Interventional

The aim of this project is to use the Exploration, Preparation, Implementation, Sustainment (EPIS) framework to collect pilot data on the implementation of a Diabetes Prevention Program-like intervention in the Women, Infants, and Children (WIC) program.

NCT ID: NCT05329610 Completed - Prediabetes Clinical Trials

β-alanine Supplementation in Adults With Overweight/Obesity

BASA-O
Start date: April 5, 2022
Phase: N/A
Study type: Interventional

The study will investigate the safety, feasibility, and efficacy of beta-alanine supplementation in adults with overweight or obesity. Beta-alanine is a widely used dietary supplement that can increase the amount of carnosine in skeletal muscle. Both carnosine and beta-alanine occur naturally in animal food products and previous research shows that supplementation with beta-alanine leads to an improvement in exercise performance; more recently, the present investigators have shown that increasing carnosine can also help to improve cardiometabolic health, detoxify skeletal muscle, and improve glucose (sugar) uptake into muscle cells. The investigators will recruit 30 participants (15 per arm) with overweight or obesity who meet the study criteria (this accounts for up to 20% attrition - a minimum of 12 participants per arm). Those who are eligible will be required to receive three short telephone calls and attend three laboratory sessions. Participants will be randomised to receive either beta-alanine or placebo (an inactive sugar pill) for the 3-month study period. To see whether beta-alanine supplementation is feasible in this population the investigators will measure recruitment, adherence (how well people can stick to the supplement regime), the number and nature of side effects, and blinding to the intervention. Markers of cardiac function, glycaemic control, and metabolic health will also be explored. All measurements will take place before and after a 3-month supplementation period. This will provide us with novel information of the role of beta-alanine and carnosine in cardiometabolic health; and will aid in the planning of a larger randomised controlled trial to assess the efficacy of beta-alanine supplementation as a therapeutic strategy.

NCT ID: NCT05314725 Not yet recruiting - Clinical trials for Stress Hyperglycemia

Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

The aim of the study is to investigate the effect of an SGLT-2 inhibitor on postoperative hyperglycemia after acute abdominal surgery in patients without diabetes

NCT ID: NCT05264727 Recruiting - Healthy Clinical Trials

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

Start date: May 30, 2023
Phase: Phase 4
Study type: Interventional

This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.

NCT ID: NCT05242055 Recruiting - Hypertension Clinical Trials

Integrated Diagnosis and Treatment of CKD on Outcomes

Start date: February 1, 2022
Phase:
Study type: Observational [Patient Registry]

Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical prognosis of patients with different stratification. Methods: By establishing a cohort of 1000 patients with CKD and conducting long-term follow-up, integrated diagnosis and treatment for CKD was performed, namely: Regular monitoring, control of blood pressure, blood glucose, blood lipid, correction of anemia, minerals - bone metabolic abnormalities, malnutrition, acid and alkali, and electrolyte disorder, diet and exercise, such as the guidance of integrated management, non intrusive, observational studies, prospective cohort were analyzed retrospectively, describe the implementation of the integration of diagnosis and treatment, chronic kidney disease (CKD) Stratified analysis and risk factor analysis were performed for cardiovascular disease and other main endpoint events, so as to objectively reflect the status of integrated treatment of CKD and provide data support for continuous quality improvement of CKD diagnosis and treatment and improvement of clinical prognosis of patients.

NCT ID: NCT05236751 Completed - Hyperglycemia Clinical Trials

Hyperglycemia in Neurosurgery

Start date: May 24, 2021
Phase:
Study type: Observational

Poor glycemic control is recognized as a risk factor for postoperative infection. For the neurosurgical patient, postoperative infection can lead to devastating complications such as meningitis, encephalitis and death. Neurosurgical patients often receive high doses of medications that increase blood glucose levels such as steroids, placing them at a potentially higher risk for postoperative infection. The purpose of this multisite observational study is to assess the impact of severe intraoperative hyperglycemia as a risk factor for postoperative infection in the neurosurgical patient.

NCT ID: NCT05231642 Completed - Type 1 Diabetes Clinical Trials

Individualised Postprandial Glucose Responses in Type 1 Diabetes

Start date: November 30, 2021
Phase: N/A
Study type: Interventional

Type 1 diabetes (T1D) is a lifelong disease which stops the body from producing insulin - an important hormone that controls blood sugar (glucose) levels. People with T1D use insulin replacement therapy, usually in the form of injections, to help control blood glucose levels, however keeping glucose levels within normal ranges is usually a challenge. Mealtime glucose control is fundamental to good diabetes management and are an important contributor to long-term diabetes complications. However, many individuals experience variability in glucose levels around mealtimes. The objective of this study is to establish whether and which parameters are important predictors of mealtime glucose levels in people with T1D. The investigators will monitor glucose levels using the latest glucose monitoring technology and collect blood samples to: 1. Characterise changes in glucose levels in individuals with T1D in response to different meals 2. Determine whether and what food characteristics and personal factors are linked to individual glucose responses to different meals. The investigators will recruit 150 individuals with type 1 diabetes. Firstly participants will attend a preliminary visit, where a blood sample will be donated to study laboratory blood markers of vascular and metabolic health accompanied by a full medical examination in which body composition will be established. During this visit participants will also complete questionnaires about their lifestyle, and be fitted with two wearable devices to monitor glucose levels and physical activity levels under free-living conditions. After 4-weeks of wearing the devices, participants will attend two experimental laboratory visits where breakfast and lunch will be served and blood samples taken. This will enable us to observe glucose and metabolic responses to feeding under controlled conditions.